ArticleNeurogenetics2026
Genetic findings in a Turkish clinical cohort with hereditary Parkinson's disease.
Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeParkinson's disease (PD) is a multifactorial neurodegenerative disorder driven by a complex interplay of genetic and environmental factors. This study aimed to characterize the mutational spectrum in a cohort of patients with clinically suspected hereditary PD using complementary genetic testing approaches. MATERIALS AND
methodsA total of 36 patients underwent genetic evaluation. Targeted next-generation sequencing (NGS) of a 10-gene PD panel was performed in 35 patients, Multiplex ligation-dependent probe amplification (MLPA)-based copy-number analysis using an 8-gene panel was conducted in 9 patients, and targeted Sanger sequencing was performed in one patient with a known familial PRKN variant.
resultsThe most clinically relevant findings involved the PRKN gene. A homozygous pathogenic variant in the PRKN gene was detected in 3 patients, compound heterozygous deletions involving the PRKN and PACRG genes in one patient, and a single heterozygous PRKN variant classified as pathogenic was detected in one patient. Additionally, variants of uncertain significance were identified in 7 patients in the ATP13A2, PRKN, VPS35, PINK1, and PLA2G6 genes.
conclusionUsing complementary molecular genetic techniques, we identified clinically relevant genetic findings in a cohort of 36 patients with suspected hereditary Parkinson's disease. These findings provide population-specific data on the mutational spectrum of PD in a Turkish clinical cohort and contribute to the characterization of the regional genetic landscape.
Indexed as
Identifiers
42836888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.